| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 1421.6 | 1374.8 | 1170.4 |
| Other income | 61.4 | 25.0 | 18.1 |
| Total income | 1483.1 | 1399.8 | 1188.5 |
| Profit before exceptional items & tax | 347.1 | 358.6 | 269.4 |
| Profit before tax | 347.1 | 358.6 | 269.4 |
| Net profit | 266.7 | 273.8 | 225.3 |
| Operating margin | 23.4% | 25.6% | 22.7% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +18.40% |
|---|---|
| Net profit, quarter on quarter | -2.60% |
| Revenue, year on year | +21.50% |
BSE results filing, NSE: AJANTPHARM. Figures extracted from the filing.
Ajanta Pharma Ltd: key numbers
- Share price
- ₹3,547.80
- Market cap
- ₹44,333 Cr
- Revenue (annual)
- ₹5,453 Cr
- Net profit (annual)
- ₹1,056 Cr
- P/E (TTM)
- 39.1×Sector 50.4×
- Promoter holding
- 63.48%-2.77% QoQ
- FII holding
- 7.68%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Ajanta Pharma Ltd
All →Ajanta Pharma Share Pledge
Aayush Agrawal (Trustee of Aayush Agrawal Trust) has released a pledge on 1,736,353 equity shares of Ajanta Pharma Limited. This follows loan repayment.
Ajanta Pharma Earnings Call Transcript: Key Takeaways
Ajanta Pharma reports strong Q1 FY27 results, but management remains cautious about sustainability, guiding for normalization in the US and acknowledging geopolitical headwinds in Asia.
- Call
- Guides 18% growth
Ajanta Pharma Q1 FY27 Results: Net Profit ₹334.2 Cr, Up 30.9% YoY
Ajanta Pharma Ltd reported revenue from operations of ₹1,626 Cr (+24.8% YoY) and net profit of ₹334.2 Cr (+30.9% YoY) for Q1 FY27.
- Key figure
- Net profit ₹334.2 Cr · +30.9% YoY
Ajanta Pharma Earnings Call: Key Takeaways
Ajanta Pharma achieved record FY26 revenue >₹5,000cr and PAT >₹1,000cr, driven by strong US and Africa performance despite Asia supply chain headwinds.
Ajanta Pharma Earnings Call: Key Takeaways
Ajanta Pharma hit major milestones in FY26, surpassing ₹5,000cr revenue and ₹1,000cr PAT, but faces logistics-driven volatility in Asia and rising costs from Middle East conflicts.